Skip to main content
SpringerLink
Log in

Plurihormonal Adenomas

  • Chapter
  • First Online:
Prolactin Disorders

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Plurihormonal or mixed anterior pituitary adenomas are derived from a single (monomorphous) or mixed cell (polymorphous) lineage and are characterized by expression of two or more pituitary hormones. These adenomas comprise approximately 10–30% of resected adenomas and most commonly immunostain positively for growth hormone (GH) and prolactin (PRL). Expression of other anterior pituitary hormones, including adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), may also occur.

Since some pituitary tumors may be silent, clinical signs, symptoms, or elevated hormone levels can be absent. Management of plurihormonal adenomas is guided by clinical presentation, the degree and expression of pituitary hormones, and local mass effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lloyd RV, Osamura RY, Klöppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.

    Google Scholar 

  2. Ho DM, Hsu CY, Ting LT, Chiang H. Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification. Histopathology. 2001;39(3):310–9.

    Article  CAS  PubMed  Google Scholar 

  3. Kageyama K, Ikeda H, Nigawara T, Sakihara S, Suda T. Expression of adrenocorticotropic hormone, prolactin and transcriptional factors in clinically nonfunctioning pituitary adenoma. Endocr J. 2007;54(6):961–8.

    Article  CAS  PubMed  Google Scholar 

  4. Matsuno A, Teramoto A, Takekoshi S, Sanno N, Osamura RY, Kirino T. HGH, PRL, and ACTH gene expression in clinically nonfunctioning adenomas detected with nonisotopic in situ hybridization method. Endocr Pathol. 1995;6(1):13–20.

    Article  CAS  PubMed  Google Scholar 

  5. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003;112(11):1603–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011;7(5):257–66.

    Article  CAS  PubMed  Google Scholar 

  7. Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2015;26(4):349–55.

    Article  CAS  PubMed  Google Scholar 

  8. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci U S A. 2003;100(3):1034–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Giacomini D, Paez-Pereda M, Theodoropoulou M, Gerez J, Nagashima AC, Chervin A, et al. Bone morphogenetic protein-4 control of pituitary pathophysiology. Front Horm Res. 2006;35:22–31.

    Article  CAS  PubMed  Google Scholar 

  10. Chanson P, Maiter D. Prolactinoma. In: Melmed S, editor. The pituitary. 4th ed. Cambridge, MA: Elsevier; 2017. p. 467–514.

    Chapter  Google Scholar 

  11. Mitrofanova LB, Konovalov PV, Krylova JS, Polyakova VO, Kvetnoy IM. Plurihormonal cells of normal anterior pituitary: facts and conclusions. Oncotarget. 2017;8(17):29282–99.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Horvath E, Kovacs K. Fine structural cytology of the adenohypophysis in rat and man. J Electron Microsc Tech. 1988;8(4):401–32.

    Article  CAS  PubMed  Google Scholar 

  13. Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab. 2010;95(1):13–7.

    Article  CAS  PubMed  Google Scholar 

  14. Dubuis JM, Deal CL, Drews RT, Goodyer CG, Lagace G, Asa SL, et al. Mammosomatotroph adenoma causing gigantism in an 8-year old boy: a possible pathogenetic mechanism. Clin Endocrinol. 1995;42(5):539–49.

    Article  CAS  Google Scholar 

  15. Stefaneanu L, Kovacs K, Horvath E, Asa SL, Losinski NE, Billestrup N, et al. Adenohypophysial changes in mice transgenic for human growth hormone-releasing factor: a histological, immunocytochemical, and electron microscopic investigation. Endocrinology. 1989;125(5):2710–8.

    Article  CAS  PubMed  Google Scholar 

  16. Asa SL, Kovacs K, Stefaneanu L, Horvath E, Billestrup N, Gonzalez-Manchon C, et al. Pituitary adenomas in mice transgenic for growth hormone-releasing hormone. Endocrinology. 1992;131(5):2083–9.

    Article  CAS  PubMed  Google Scholar 

  17. Ghazi AA, Amirbaigloo A, Dezfooli AA, Saadat N, Ghazi S, Pourafkari M, et al. Ectopic acromegaly due to growth hormone releasing hormone. Endocrine. 2013;43(2):293–302.

    Article  CAS  PubMed  Google Scholar 

  18. Weiss DE, Vogel H, Lopes MB, Chang SD, Katznelson L. Ectopic acromegaly due to a pancreatic neuroendocrine tumor producing growth hormone-releasing hormone. Endocr Pract. 2011;17(1):79–84.

    Article  PubMed  Google Scholar 

  19. Moran A, Asa SL, Kovacs K, Horvath E, Singer W, Sagman U, et al. Gigantism due to pituitary mammosomatotroph hyperplasia. N Engl J Med. 1990;323(5):322–7.

    Article  CAS  PubMed  Google Scholar 

  20. Losa M, von Werder K. Pathophysiology and clinical aspects of the ectopic GH-releasing hormone syndrome. Clin Endocrinol. 1997;47(2):123–35.

    Article  CAS  Google Scholar 

  21. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery. 2006;59(2):341–53.. discussion -53

    Article  PubMed  Google Scholar 

  22. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab. 2010;95(4):1708–16.

    Article  CAS  PubMed  Google Scholar 

  23. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, et al. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol. 2011;21(5):533–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Xiao JQ, Liu XH, Hou B, Yao Y, Deng K, Feng M, et al. Correlations of pituitary tumor transforming gene expression with human pituitary adenomas: a meta-analysis. PLoS One. 2014;9(3):e90396.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178(3):265–76.

    Article  CAS  PubMed  Google Scholar 

  26. Wang P, Wang T, Yang Y, Yu C, Liu N, Yan C. Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas: a case report and review of the literatures. Medicine (Baltimore). 2017;96(49):e9056.

    Article  Google Scholar 

  27. Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, et al. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016;7(47):76565–76.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93(4):1412–7.

    Article  CAS  PubMed  Google Scholar 

  29. Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol. 2018;31:900–9.

    Article  CAS  PubMed  Google Scholar 

  30. Greenman Y, Melmed S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab. 1994;79(3):724–9.

    CAS  PubMed  Google Scholar 

  31. Kabuto M, Kubota T, Kobayashi H, Nakagawa T, Kitai R, Kodera T. Detection of mammosomatotroph cells and identification of the coexistence of growth hormone and prolactin within the same secretory granules in these cells using confocal laser scanning microscopy. Histochem Cell Biol. 1995;104(5):363–7.

    Article  CAS  PubMed  Google Scholar 

  32. Felix IA, Horvath E, Kovacs K, Smyth HS, Killinger DW, Vale J. Mammosomatotroph adenoma of the pituitary associated with gigantism and hyperprolactinemia. A morphological study including immunoelectron microscopy. Acta Neuropathol. 1986;71(1–2):76–82.

    Article  CAS  PubMed  Google Scholar 

  33. Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51.

    Article  CAS  PubMed  Google Scholar 

  34. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab. 2001;86(9):4072–7.

    Article  CAS  PubMed  Google Scholar 

  35. Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016;12(2):90–8.

    Article  CAS  PubMed  Google Scholar 

  36. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol. 2004;61(2):209–15.

    Article  CAS  Google Scholar 

  37. Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152(4):569–74.

    Article  CAS  PubMed  Google Scholar 

  38. Langlois F, Woltjer R, Cetas JS, Fleseriu M. Silent somatotroph pituitary adenomas: an update. Pituitary. 2018;21:194–202.

    Article  PubMed  Google Scholar 

  39. Syro LV, Rotondo F, Serna CA, Ortiz LD, Kovacs K. Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary. Pituitary. 2017;20(1):84–92.

    Article  CAS  PubMed  Google Scholar 

  40. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol. 2007;156(2):203–16.

    Article  CAS  PubMed  Google Scholar 

  41. Lopes MB. Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus. 2010;29(4):E2.

    Article  PubMed  Google Scholar 

  42. Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-1 values? Pituitary. 2012;15(4):562–70.

    Article  CAS  PubMed  Google Scholar 

  43. Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M. Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol. 2006;59(3):274–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat Rev Cancer. 2004;4(4):285–95.

    Article  CAS  PubMed  Google Scholar 

  45. Horvath E, Kovacs K, Singer W, Smyth HS, Killinger DW, Erzin C, et al. Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer. 1981;47(4):761–71.

    Article  CAS  PubMed  Google Scholar 

  46. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88.

    Article  CAS  PubMed  Google Scholar 

  47. Mete O, Gomez-Hernandez K, Kucharczyk W, Ridout R, Zadeh G, Gentili F, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol. 2016;29(2):131–42.

    Article  CAS  PubMed  Google Scholar 

  48. Azzalin A, Appin CL, Schniederjan MJ, Constantin T, Ritchie JC, Veledar E, et al. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary. 2016;19(2):183–93.

    Article  PubMed  Google Scholar 

  49. Malchiodi E, Profka E, Ferrante E, Sala E, Verrua E, Campi I, et al. Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab. 2014;99(6):2069–76.

    Article  CAS  PubMed  Google Scholar 

  50. Bertholon-Gregoire M, Trouillas J, Guigard MP, Loras B, Tourniaire J. Mono- and plurihormonal thyrotropic pituitary adenomas: pathological, hormonal and clinical studies in 12 patients. Eur J Endocrinol. 1999;140(6):519–27.

    Article  CAS  PubMed  Google Scholar 

  51. Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W. Silent adenoma subtype 3 of the pituitary – immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol. 2005;29(6):511–24.

    Article  CAS  PubMed  Google Scholar 

  52. Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, et al. Pathology of the human pituitary adenomas. Histochem Cell Biol. 2008;130(3):495–507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol. 2017;28(3):228–43.

    Article  CAS  PubMed  Google Scholar 

  54. Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, et al. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol. 2009;71(1):92–9.

    Article  CAS  Google Scholar 

  55. Pereira BD, Raimundo L, Mete O, Oliveira A, Portugal J, Asa SL. Monomorphous plurihormonal pituitary adenoma of Pit-1 lineage in a giant adolescent with central hyperthyroidism. Endocr Pathol. 2016;27(1):25–33.

    Article  PubMed  Google Scholar 

  56. Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J. Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary. 2015;18(3):326–34.

    Article  PubMed  Google Scholar 

  57. Richardson TE, Shen ZJ, Kanchwala M, Xing C, Filatenkov A, Shang P, et al. Aggressive behavior in silent subtype III pituitary adenomas may depend on suppression of local immune response: a whole transcriptome analysis. J Neuropathol Exp Neurol. 2017;76(10):874–82.

    Article  CAS  PubMed  Google Scholar 

  58. Langlois F, Lim DST, Varlamov E, Yedinak CG, Cetas JS, McCartney S, et al. Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine. 2017;58(3):528–34.

    Article  CAS  PubMed  Google Scholar 

  59. Cho HY, Cho SW, Kim SW, Shin CS, Park KS, Kim SY. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol. 2010;72(5):648–53.

    Article  Google Scholar 

  60. Ioachimescu AG, Eiland L, Chhabra VS, Mastrogianakis GM, Schniederjan MJ, Brat D, et al. Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas. Neurosurgery. 2012;71(2):296–303. discussion 4.

    Article  PubMed  Google Scholar 

  61. Ben-Shlomo A, Cooper O. Silent corticotroph adenomas. Pituitary. 2018;21(2):183–93.

    Article  CAS  PubMed  Google Scholar 

  62. Brown RL, Muzzafar T, Wollman R, Weiss RE. A pituitary carcinoma secreting TSH and prolactin: a non-secreting adenoma gone awry. Eur J Endocrinol. 2006;154(5):639–43.

    Article  CAS  PubMed  Google Scholar 

  63. Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JM, et al. Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab. 1993;76(2):529–33.

    CAS  PubMed  Google Scholar 

  64. Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002;87(2):457–65.

    Article  CAS  PubMed  Google Scholar 

  65. Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol. 2007;67(4):613–22.

    Google Scholar 

  66. Uraki S, Ariyasu H, Doi A, Furuta H, Nishi M, Usui T, et al. Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy. Endocrinol Diabetes Metab Case Rep. 2017;2017:1–8.

    Google Scholar 

  67. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32(4):534–43.

    Article  PubMed  Google Scholar 

  68. Yao Y, Liu Y, Wang L, Deng K, Yang H, Lu L, et al. Clinical characteristics and management of growth hormone excess in patients with McCune-Albright syndrome. Eur J Endocrinol. 2017;176(3):295–303.

    Article  CAS  PubMed  Google Scholar 

  69. Madsen H, Borges MT, Kerr JM, Lillehei KO, Kleinschmidt-Demasters BK. McCune-Albright syndrome: surgical and therapeutic challenges in GH-secreting pituitary adenomas. J Neuro-Oncol. 2011;104(1):215–24.

    Article  CAS  Google Scholar 

  70. Correa R, Salpea P, Stratakis CA. Carney complex: an update. Eur J Endocrinol. 2015;173(4):M85–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Kurtkaya-Yapicier O, Scheithauer BW, Carney JA, Kovacs K, Horvath E, Stratakis CA, et al. Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study. Ultrastruct Pathol. 2002;26(6):345–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pituitary Center, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

    Artak Labadzhyan & Shlomo Melmed

Authors
  1. Artak Labadzhyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shlomo Melmed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Artak Labadzhyan .

Editor information

Editors and Affiliations

  1. Neuroendocrine and Pituitary Clinical Center, Massachusetts General Hospital, Boston, MA, USA

    Nicholas A. Tritos

  2. Neuroendocrine and Pituitary Clinical Center, Massachusetts General Hospital, Boston, MA, USA

    Anne Klibanski

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Labadzhyan, A., Melmed, S. (2019). Plurihormonal Adenomas. In: Tritos, N., Klibanski, A. (eds) Prolactin Disorders. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-11836-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11836-5_12

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-11835-8

  • Online ISBN: 978-3-030-11836-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation